Merck provides overview of clinical trial program for HPV vaccine V503

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the company's investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Food and Drug Administration in 2013.

The study evaluated the efficacy, immunogenicity and safety of V503 in females 16-26 years of age. Merck plans to present results from this study, as well as other results from the Phase III clinical program for V503, at the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) congress in November.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Multivalent mRNA-based vaccine may serve as a preventative measure against future flu pandemics